Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,063,202
  • Shares Outstanding, K 161,974
  • Annual Sales, $ 705,140 K
  • Annual Income, $ -453,900 K
  • EBIT $ -278 M
  • EBITDA $ -287 M
  • 60-Month Beta 0.30
  • Price/Sales 18.46
  • Price/Cash Flow N/A
  • Price/Book 21.06

Options Overview Details

View History
  • Implied Volatility 48.91% (-1.63%)
  • Historical Volatility 30.02%
  • IV Percentile 45%
  • IV Rank 25.54%
  • IV High 86.76% on 04/09/25
  • IV Low 35.92% on 09/08/25
  • Expected Move (DTE 21) 6.63 (8.27%)
  • Put/Call Vol Ratio 1.53
  • Today's Volume 81
  • Volume Avg (30-Day) 464
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 34,345
  • Open Int (30-Day) 34,843
  • Expected Range 73.57 to 86.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.32
  • Number of Estimates 9
  • High Estimate -0.95
  • Low Estimate -1.62
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.69 +4.35%
on 12/18/25
83.61 -4.28%
on 12/04/25
-2.67 (-3.23%)
since 11/26/25
3-Month
63.36 +26.31%
on 09/29/25
83.61 -4.28%
on 12/04/25
+15.94 (+24.87%)
since 09/26/25
52-Week
23.95 +234.15%
on 04/09/25
83.61 -4.28%
on 12/04/25
+43.70 (+120.29%)
since 12/26/24

Most Recent Stories

More News
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

– First and only investigational medicine for this rare, often fatal neurological condition – – On track to submit new drug application (NDA) in Q1 2026 –

IONS : 80.20 (-0.56%)
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

– On track to submit supplemental new drug application by end of year –

IONS : 80.20 (-0.56%)
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg...

IONS : 80.20 (-0.56%)
BIIB : 176.17 (-0.09%)
Biogen Completes Acquisition of Alcyone Therapeutics

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative...

IONS : 80.20 (-0.56%)
BIIB : 176.17 (-0.09%)
DAWNZERAâ„¢ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Recommendation based on breadth of clinical evidence demonstrating significant HAE attack rate reduction with DAWNZERA European Commission decision expected...

IONS : 80.20 (-0.56%)
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity

IONS : 80.20 (-0.56%)
Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Healthcare Conference...

IONS : 80.20 (-0.56%)
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity

IONS : 80.20 (-0.56%)
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

– Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months – – 86% of olezarsen-treated...

IONS : 80.20 (-0.56%)
Ionis presents new data demonstrating long-term disease control with DAWNZERAâ„¢ (donidalorsen) at ACAAI 2025 Annual Meeting

DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label extension study Patients...

IONS : 80.20 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 81.69
2nd Resistance Point 81.36
1st Resistance Point 81.00
Last Price 80.20
1st Support Level 80.31
2nd Support Level 79.98
3rd Support Level 79.62

See More

52-Week High 83.61
Last Price 80.20
Fibonacci 61.8% 60.82
Fibonacci 50% 53.78
Fibonacci 38.2% 46.74
52-Week Low 23.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar